Table 2.
Proportion of Patients With an Immune Response 12 Weeks After the First SARS-CoV-2 Vaccination
| SHCS and STCS | SHCS | STCS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| mRNA-1273 (Moderna) |
BNT162b2 (Pfizer-BioNTech) | Total | Difference | mRNA-1273 (Moderna) |
BNT162b2 (Pfizer-BioNTech) | Total | mRNA-1273 (Moderna) |
BNT162b2 (Pfizer-BioNTech) | Total | |
| Intention to treat | ||||||||||
| Immune response (Elecsys S [14])a | 92.1% (88.4; 95.8%) 186/202 |
94.3% (91.2; 97.4%) 198/210 |
93.2% (90.8; 95.6%) 384/412 |
–2.2% (–7.1; 2.7%) | 100.0% (-) 169/169 |
100.0% (-) 172/172 |
100.0% (-) 341/341 |
51.5% (34.5; 68.6%) 17/33 |
68.4% (53.6; 83.2%) 26/38 |
60.6% (49.2; 71.9%) 43/71 |
| Immune response (ABCORA2 [15]) | 89.1% (84.8; 93.4%) 180/202 |
89.5% (85.4; 93.7%) 188/210 |
89.3% (86.3; 92.3%) 368/412 |
–0.4% (–6.4;5.6%) |
100.0% (-)169/169 |
99.4% (98.3; 100.0%) 171/172 |
99.7% (99.1–100.0) 340/341 |
33.3% (17.3; 49.4%) 11/33 |
44.7% (28.9; 60.6%) 17/38 |
39.4% (28.1; 50.8%) 28/71 |
| Per-protocolb | ||||||||||
| Immune response (Elecsys S [14])a | 92.0% (88.2; 95.8%) 184/200 |
94.6% (91.5; 97.7%) 193/204 |
93.3% (90.9; 95.8%) 377/404 |
–2.6% (–7.5;2.3%) | 100.0% (-) 168/168 |
100.0% (-) 170/170 |
100.0% (-) 338/338 |
50.0% (32.7; 67.3%) 16/32 |
67.7% (51.9; 83.4%) 23/34 |
59.1% (47.2; 71.0%) 39/66 |
| Immune response (ABCORA 2 [15]) | 89.0% (84.7; 93.3%) 178/200 |
89.7% (85.5; 93.9%) 183/204 |
89.4% (86.4; 92.4%) 361/404 |
–0.7% (–6.7; 5.3%) |
100.0% (-) 168/168 |
99.4% (98.3; 100.0%) 169/170 |
99.7% (99.1; 100.0%) 337/338 |
31.3% (15.2; 47.3%) 10/32 |
41.2% (24.6; 57.7%) 14/34 |
36.4% (24.8; 48.0%) 24/66 |
Sensitivity analysis for the per-protocol estimate, including only patients who received the intervention they were allocated to, with an interval of 4 weeks (± 1 week) between first and second vaccination dose and provided outcome data at 12 weeks (± 1 week) is available in the Supplementary Appendix.
Abbreviations: ABCORA 2, Antibody Coronavirus Assay 2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SHCS, Swiss HIV Cohort Study; STCT, Swiss Transplant Cohort Study.
Using the threshold of at 0.8 U/mL.
Including patients who received the intervention they were allocated to and have available outcome data.